Brivoligide - Adynxx
Alternative Names: AYX-1; Brivoligide-sodiumLatest Information Update: 20 Jul 2020
At a glance
- Originator Adynxx
- Class Analgesics; Oligonucleotides
- Mechanism of Action Early growth response protein 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Pain; Postoperative pain
Most Recent Events
- 09 Jul 2020 Adynxx withdraws a phase II ADYX-005 trial for Postoperative pain in patients undergoing unilateral total knee arthroplasty or TKA prior to enrolment owing to delay in trial initiation due to COVID-19 pandemic in USA (NCT03797612)
- 09 Jul 2020 Adynxx withdraws a phase II ADYX-006 trial for Postoperative pain in patients undergoing mastectomy with immediate tissue expander or implant placement prior to enrolment owing to delay in trial initiation due to COVID-19 pandemic in USA (NCT04104919)
- 14 Nov 2019 Adynxx plans the phase II ADYX-005 trial for Postoperative pain in USA in participants undergoing unilateral total knee arthroplasty or TKA in the first quarter of 2020 (NCT03797612)